<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01684111</url>
  </required_header>
  <id_info>
    <org_study_id>ABC-2011-NSCLC-05</org_study_id>
    <secondary_id>2011-003094-28</secondary_id>
    <nct_id>NCT01684111</nct_id>
  </id_info>
  <brief_title>An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)</brief_title>
  <acronym>VENUS-1</acronym>
  <official_title>An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aktion Bronchialkarzinom e.V.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aktion Bronchialkarzinom e.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the maximum tolerated dose of BIBF 1120, safety and pharmacokinetics in&#xD;
      escalating doses administered with Vinorelbine i.v. in elderly patients with advanced&#xD;
      Non-Small Lung Cancer (Stage IV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients older than 70 years could be enroled in this clinical trial. The trial is being&#xD;
      carried out in two trial centres in Germany.&#xD;
&#xD;
      For the planned sample size it is assumed that two different dosage groups are needed with 6&#xD;
      patients on each dosage group with the option to deescalate the first dosage. Altogether this&#xD;
      leads to an estimated sample size of maximal 18 patients.&#xD;
&#xD;
        -  Duration of treatment/patient: up to 6 month&#xD;
&#xD;
        -  Follow Up: at least 6 month&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the maximum tolerated dose of BIBF 1120</measure>
    <time_frame>Cycle 1 day 1, day 2, day 8, day 15; Cycle 2 day 1, day 2, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Cycle 1 day 1, day 2, day 8, day 15; Cycle 2 day 1, day 2, day 8, day 15; Cycle 3 day 1, day 8, day 15; Cycle 4 day 1, day 8, day 15; day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: Aerea Under Curve (AUC)</measure>
    <time_frame>0,15, 0,50, 1, 1,50, 2, 3, 4, 6, 7, 24, 24,15, 24,50, 25, 25,5, 26, 27, 28, 30, 31, 48, 168 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: C-max</measure>
    <time_frame>0,15, 0,50, 1, 1,50, 2, 3, 4, 6, 7, 24, 24,15, 24,50, 25, 25,5, 26, 27, 28, 30, 31, 48, 168 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Day 43 (prior start of cycle 3), day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>BIBF 1120, Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the 'Maximum Tolerated Dose', dose escalation for BIBF 1120 will be conducted following the 3 + 3 design. A cohort of three patients will be treated at the starting dose level 150mg bid and observed until the end of the first cycle.&#xD;
Under certain conditions the dose level will be escalated to 200mg bid in a second cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF 1120</intervention_name>
    <description>2 x 150 mg capsules, oral, daily (Start dose)</description>
    <arm_group_label>BIBF 1120, Vinorelbine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>25 mg/m2 i.v. on day 1 and 8 (three-week cycle)</description>
    <arm_group_label>BIBF 1120, Vinorelbine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological confirmed Non-Small-Cell lung cancer (NSCLC)&#xD;
&#xD;
          -  Tumor stage IV (UICC 7th Version)&#xD;
&#xD;
          -  ECOG &lt;2&#xD;
&#xD;
          -  Age &gt; 70 years&#xD;
&#xD;
          -  No previous chemotherapy for stage IV NSCLC (UICC 7th Version)&#xD;
&#xD;
          -  Adjuvant or neoadjuvant chemotherapy for NSCLC must be completed at least one year&#xD;
             prior to study enrolment (from end of chemotherapy)&#xD;
&#xD;
          -  Patients with prior radiation therapy may be eligible for this study if they meet the&#xD;
             following guidelines:&#xD;
&#xD;
               -  Previous radiation therapy is allowed to &lt;25% of the bone marrow (Cristy and&#xD;
                  Eckerman 1987), but should have been limited and must not have included whole&#xD;
                  pelvis radiation.&#xD;
&#xD;
               -  Patients must have recovered from the toxic effects of the treatment prior to&#xD;
                  study enrolment (except for alopecia).&#xD;
&#xD;
               -  Prior thoracic radiotherapy must be completed 30 days before study enrolment.&#xD;
&#xD;
               -  Lesions that have been irradiated cannot be included as sites of measurable&#xD;
                  disease unless clear tumour progression has been documented in these lesions&#xD;
                  since the end of radiation therapy.&#xD;
&#xD;
               -  Palliative extrathoracic radiotherapy to pre-existing lesions may continue on&#xD;
                  study; however, these lesions may not be included as sites of measurable disease.&#xD;
&#xD;
          -  Adequate haematological laboratory parameters:&#xD;
&#xD;
               -  Haemoglobin ≥9 g/dl&#xD;
&#xD;
               -  WBC ≥3.000/µl&#xD;
&#xD;
               -  Platelets ≥100.000/µl&#xD;
&#xD;
               -  Neutrophil count &gt; 1,500/µl&#xD;
&#xD;
          -  Adequate renal laboratory parameters&#xD;
&#xD;
               -  Creatinine ≤1,9 mg/dl&#xD;
&#xD;
               -  Creatinine Clearance &gt; 45 ml/min&#xD;
&#xD;
          -  Adequate hepatic function&#xD;
&#xD;
               -  Total bilirubin within normal range&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x ULN (patients with liver metastasis)&#xD;
&#xD;
               -  ALT &lt; 1.5 x ULN&#xD;
&#xD;
               -  ALT &lt; 2.5 x ULN (patients with liver metastasis)&#xD;
&#xD;
               -  AST &lt; 1.5 x ULN&#xD;
&#xD;
               -  AST &lt; 2.5 x ULN (patients with liver metastasis)&#xD;
&#xD;
               -  Alk. phosphatase &lt; 3 x ULN&#xD;
&#xD;
               -  LDH &lt; 5 x ULN ULN = Upper Limit Of Normal (ULN)&#xD;
&#xD;
          -  Other lab parameters:&#xD;
&#xD;
               -  Proteinuria &lt; CTCAE grade 2&#xD;
&#xD;
               -  Prothrombin time and/or partial thromboplastin time &lt; 50 % deviation from normal&#xD;
                  limits&#xD;
&#xD;
          -  Informed consent, personally signed and dated to participate in the study&#xD;
&#xD;
          -  Male patients enrolled in this trial must use adequate barrier birth control measures&#xD;
             during the course of treatment and for at least 3 months after the last administration&#xD;
             of study therapy&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any severe concomitant condition which makes it undesirable for the patient to&#xD;
             participate in the study or which could jeopardise compliance with the protocol&#xD;
&#xD;
          -  Serious infections requiring systemic antibiotic (e.g antiviral, antimicrobial,&#xD;
             antifungal) therapy&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer or bone fracture or major injuries and/or surgery&#xD;
             within 4 weeks of trial inclusion, or planned surgical procedures during the trial&#xD;
             period.&#xD;
&#xD;
          -  Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
          -  Known hypersensitivity to the trial drugs or their excipients.&#xD;
&#xD;
          -  History of other malignancies in the last 5 years, in particular those which could&#xD;
             affect compliance with the protocol or interpretation of results. Patients with&#xD;
             adequately treated basal or squamous cell skin cancer are generally eligible.&#xD;
&#xD;
          -  Serious concomitant disease, especially those that would limit compliance with trial&#xD;
             requirements or which are considered relevant for the evaluation of the efficacy or&#xD;
             safety of the trial drug, such as neurologic, psychiatric, infectious disease or&#xD;
             active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may&#xD;
             increase the risk associated with trial participation or trial drug administration,&#xD;
             and in the judgment of the investigator would make the patient inappropriate for entry&#xD;
             into the trial.&#xD;
&#xD;
          -  Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina,&#xD;
             history of infarction within past 9 months, congestive heart failure &gt; NYHA II)&#xD;
&#xD;
          -  Known inherited predisposition to bleeds or to thrombosis.&#xD;
&#xD;
          -  Patient with brain metastases that are symptomatic and/or require therapy.&#xD;
&#xD;
          -  Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed&#xD;
             for maintenance of an indwelling intravenous device) or antiplatelet therapy(except&#xD;
             for chronic low-dose therapy with acetylsalicylic acid ≤325mg per day)&#xD;
&#xD;
          -  History of major thrombotic events or clinically relevant major bleeding event in the&#xD;
             past 6 months (excluding central venous catheter thrombosis and peripheral deep vein&#xD;
             thrombosis below the joint space of the knee)&#xD;
&#xD;
          -  Current peripheral neuropathy ≥ CTCAE grade 2 except due to trauma&#xD;
&#xD;
          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of&#xD;
             the study drug&#xD;
&#xD;
          -  Active alcohol or drug abuse.&#xD;
&#xD;
          -  Men who are sexually active and unwilling to use a medically acceptable method of&#xD;
             contraception&#xD;
&#xD;
          -  Leptomeningeal disease&#xD;
&#xD;
          -  Radiographic evidence of cavitary or necrotic tumours&#xD;
&#xD;
          -  Centrally located tumours with radiographic evidence (CT or MRI) of local invasion of&#xD;
             major blood vessels&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>71 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. Rudolf M. Huber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München, D-80336 München</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Dr. Martin Wolf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum Kassel GmbH, D-34125 Kassel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LungenClinic Großhansdorf GmbH</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>D-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>August 28, 2012</study_first_submitted>
  <study_first_submitted_qc>September 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2012</study_first_posted>
  <last_update_submitted>January 15, 2016</last_update_submitted>
  <last_update_submitted_qc>January 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer - Stage IV</keyword>
  <keyword>NSCLC Stage IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

